iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 14 **Issue:** VII **Month of publication:** July 2026

DOI: https://doi.org/10.22214/ijraset.2026.84197

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 14 Issue VII July 2026- Available at www.ijraset.com

Review On: Quality by Design (QbD) in Modern Pharmaceutical Development

Miss. Sayali Rajesh Bhalsen[1], Mr. Nilesh D. Zanzane[2], Dr. Nitin M Gawai[3], Miss. Asmita D Tengle[4], Miss. Vaidehi V Tukrul[5]
B. Pharmacy Department, Mahadev Kanchan College Of Pharmaceutical Education And Research, Ajinkya Charitable Foundation, Uruli Kanchan, Pin Code-412202, Pune, India

Abstract: ***The pharmaceutical industry is currently undergoing a significant shift from empirical, reactive manufacturing strategies to a systematic, predictive framework known as Quality by Design (QbD). By transitioning from traditional post-production inspection—where quality is "tested into" the product—to a proactive strategy where quality is "built into" the design, organizations can better navigate the complexities of pharmaceutical development. This article provides an in-depth analysis of the QbD paradigm, anchored by the International Council for Harmonization (ICH) guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System). We delineate the critical transition from "fixed" manufacturing processes to flexible, science-based "Design Spaces," supported by Process Analytical Technology (PAT) and real-time release testing. The review examines the integrated elements of QbD, including the formulation of the Quality Target Product Profile (QTPP), the systematic identification of Critical Quality Attributes (CQAs), and the application of Failure Mode and Effects Analysis (FMEA) for comprehensive risk mitigation. Furthermore, we explore how Design of Experiments (DoE) and multivariate data analysis (MVDA) serve as pillars for enhancing process understanding and enabling continuous lifecycle improvement. By evaluating the strategic implications of these methodologies, this review demonstrates how QbD not only ensures consistent patient safety and product efficacy but also provides significant economic advantages by reducing batch failure rates, accelerating regulatory approval timelines, and facilitating agile manufacturing in an increasingly globalized market.***

Keywords: Quality by Design (QbD), Process Analytical Technology (PAT), Quality target Product Profile, Critical quality attributes.

I. INTRODUCTION

Pharmaceutical quality was assured through post-manufacturing testing and inspection of the final product. However, this empirical, reactive approach often failed to identify the root causes of variability. QbD, a concept pioneered by Dr. Joseph M. Juran, posits that quality crises arise from flawed product design and that quality must be "designed into" the product from the outset.

The FDA and international regulatory bodies now encourage the adoption of QbD because it fosters a comprehensive understanding of how critical process parameters (CPPs) and raw material attributes influence final product quality attributes (CQAs).

The philosophy of QbD is rooted in the work of Dr. Joseph M. Juran, who emphasized that quality crises are primarily failures of design, not execution. In the pharmaceutical industry, this framework has been formalized through the International Council for Harmonisation (ICH) guidelines, specifically:

- ICH Q8 (R2): Focuses on pharmaceutical development and the definition of a systematic approach.
- ICH Q9: Provides the framework for Quality Risk Management (QRM).
- ICH Q10: Details the Pharmaceutical Quality System (PQS) necessary to support the lifecycle of a product.

A. Benefits of the QbD Approach

By shifting toward this science- and risk-based methodology, the pharmaceutical industry aims to achieve several strategic objectives:

1) Enhanced Process Understanding: By utilizing tools such as Design of Experiments (DoE) and Process Analytical Technology (PAT), manufacturers can define the "design space," allowing for greater flexibility and reduced regulatory burden for post-approval changes.
2) Reduced Patient Risk: Proactive identification of variables that influence quality ensures consistent performance, thereby minimizing the risk of sub-standard products reaching the patient.

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 14 Issue VII July 2026- Available at www.ijraset.com

3) Continuous Improvement: QbD fosters a lifecycle approach to quality, where product and process knowledge is iteratively refined, leading to more robust manufacturing processes and reduced manufacturing variances.

II. QBD VS. TRADITIONAL APPROACH

The transition from traditional practices to a QbD framework involves several fundamental changes in manufacturing strategy:-

Feature	Qbd Approach	Traditional Approach
Quality Strategy	Risk-based, Design-based	Testing & Inspection
Process Control	Flexible Process (within design space)	Frozen (fixed) Process
Development	Systematic, scientific	Empirical
Lifecycle View	Continuous verification & improvement	Limited

Flow Chart: - Difference between Qbd Approach and Traditional Approach

III. CORE ELEMENTS OF QBD

The effectiveness of QbD relies on the systematic integration of several key elements:

1) Quality Target Product Profile (QTPP): "Beginning with the end in mind," QTPP is a prospective summary of the quality characteristics required to ensure the desired safety and efficacy.
2) Critical Quality Attributes (CQAs): Physical, chemical, biological, or microbiological properties that must remain within defined limits to ensure product quality.
3) Risk Assessment: A science-based process, often utilizing tools like Failure Mode and Effects Analysis (FMEA), to identify and mitigate factors that could jeopardize product quality.
4) Design Space: The established range of process parameters and input attributes that provide assurance of quality. Operating within this space is not considered a change, allowing for greater manufacturing flexibility.
5) Control Strategy: A planned set of controls derived from process understanding that ensures performance throughout the product lifecycle.

IV. METHODOLOGY AND TOOLS

A. Design of Experiments (DoE)

Design of Experiments (DoE) is the primary statistical methodology used to explore the relationship between process inputs and product quality.

1) Efficiency: Unlike traditional methods that change one variable at a time (OVAT), which is inefficient and ignores how factors interact, DoE evaluates multiple variables simultaneously.
2) Optimization: DoE identifies the "sweet spot" for process parameters—such as temperature, pH, or mixing speed—that ensures the final drug product consistently meets all predefined quality standards.
3) Statistical Significance: It provides a mathematical foundation to distinguish between significant factors that directly impact product quality and minor noise that does not.

B. Process Analytical Technology (PAT)

PAT is the technological engine that enables real-time monitoring and control during the actual manufacturing process.

1) Real-Time Insight: By integrating sensors and analytical probes directly into the manufacturing line, companies can observe physical or chemical changes as they happen, rather than waiting days for lab results.

2) Analytical Techniques: Common tools include Near-Infrared (NIR) spectroscopy, Raman spectroscopy, and high-performance liquid chromatography (HPLC) sensors.
3) Reduced Variability: By monitoring Critical Process Parameters (CPPs) in real time, manufacturers can make micro-adjustments during the process to keep the product within the "Design Space," effectively preventing failures before they occur.

C. Risk Assessment Tools

To manage potential hazards, QbD relies on structured risk management frameworks, most notably those outlined in ICH Q9.
Failure Mode and Effects Analysis (FMEA): This is the most common tool used to rank risks. It assigns a score to every step in the process based on:

1) Severity: How bad would the outcome be if this step failed?
2) Occurrence: How likely is the failure to happen?
3) Detectability: How easily can we catch this error before it impacts the patient?
4) Prioritization: By ranking these risks, teams can focus their limited resources on the most critical parts of the process, ensuring that the highest risks receive the most robust control strategies.

D. Mathematical Modeling and Simulation

Modern QbD frequently utilizes computer-based simulations to predict outcomes without having to run expensive physical trials.

1) Mechanistic Models: These use mathematical equations to describe the physical behavior of a process, such as how long it takes for a tablet to dissolve based on its chemical composition.
2) Computational Fluid Dynamics (CFD): This helps engineers visualize how liquids or powders move inside large industrial mixing vessels, helping to prevent uneven blending (a common cause of batch failure).
3) Scale-up Predictability: These models are vital when moving from a small laboratory bench (grams) to a full-scale factory production line (kilograms/tons), as they predict how changing the size of the equipment will affect the final product.

V. APPLICATIONS OF QUALITY BY DESIGN

A. Drug Substance and Excipient Selection

QbD begins at the pre-formulation stage by evaluating how the physical and chemical properties of Active Pharmaceutical Ingredients (APIs) and excipients affect final performance.

- Material Attributes: Researchers identify which raw material characteristics—such as particle size, moisture content, or crystallinity—are critical to the drug's stability and bioavailability.
- Compatibility Studies: Systematic risk assessments ensure that chosen excipients do not negatively interact with the API, preventing degradation over the product's shelf life.

B. Analytical Method Development

Modern analytical methods must be as robust as the manufacturing process itself.

- Method Design Space: Scientists use DoE to determine the optimal conditions for analytical techniques (e.g., HPLC or UV-Spectroscopy).
- Validation: By understanding the limits of an analytical method, laboratories can ensure they are detecting impurities reliably, which supports the overall control strategy.

C. Formulation and Process Development

This is the core application where QbD transforms lab-scale success into industrial-scale reliability.

- QTPP Definition: Every new product begins with a Quality Target Product Profile (QTPP), defining the desired quality, safety, and efficacy standards the product must meet.
- Design Space Mapping: Through experimentation, manufacturers establish a "Design Space" where process parameters (like pressure, heat, and time) can fluctuate without compromising the Critical Quality Attributes (CQAs) of the drug.
- Scale-Up Strategy: Predictive modeling and simulation tools are used to predict how processes will behave when moving from small-scale equipment to large-scale reactors, minimizing the risk of failure during technology transfer.

D. Stability Testing and Shelf-Life Prediction

QbD principles are used to design stability programs that are more predictive and less reliant on long-term, empirical observations.

- Accelerated Modeling: By understanding the degradation pathways of a molecule through a QbD framework, scientists can more accurately predict how the drug will react to temperature and humidity over time.
- Environmental Control: These insights help establish optimal storage conditions and packaging requirements that protect the drug's integrity.

E. Regulatory Filings and Lifecycle Management

QbD shifts the relationship between the pharmaceutical company and the regulatory authority.

- Regulatory Flexibility: Because the manufacturer has established a scientifically backed Design Space, they can propose changes to their process within those parameters to regulators without requiring a time-consuming formal supplement approval.
- Continuous Improvement: ICH Q10 promotes the idea of an Pharmaceutical Quality System (PQS) that allows for ongoing improvement throughout the product's lifecycle, ensuring that the process remains optimized even after the drug has reached the market.

VI. CONCLUSION

This is a simple terms, adopting Quality by Design (QbD) changes pharmaceutical manufacturing from a reactive process of trial-and-error into a proactive, science-driven strategy. By thoroughly understanding the science behind how a medicine is made—from the quality of the raw materials to the settings on the machines—manufacturers can "build" quality into the product from the very start rather than simply hoping for the best and testing it at the end.

This shift ensures that every batch produced is consistent and reliable, which significantly reduces the chances of failure and helps prevent medicine shortages for patients. Furthermore, because the process is based on proven scientific data, companies gain the flexibility to make minor adjustments without needing lengthy regulatory approvals, ultimately leading to a more efficient and agile manufacturing environment. In conclusion, QbD represents a smarter, more modern approach to medicine production that prioritizes patient safety through deep scientific insight and continuous improvement throughout the entire lifecycle of a drug.

REFERENCES

[1] Darkunde, S. L. (2018). A review on quality by design. Int J Pharm Chem Anal, 5(1), 1-6.
[2] Kumar, V. P., & Gupta, N. V. (2015). A review on quality by design approach (QBD) for pharmaceuticals. Int. J. Drug Dev. Res, 7(1), 52-60.
[3] Kengar, M. D., Tamboli, J. A., & Magdum, C. (2019). Quality by design-a review. PharmaTutor, 7(4), 48-51.
[4] Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. The AAPS journal, 16(4), 771-783.
[5] Kumar, V. P., & Gupta, N. V. (2015). A review on quality by design approach (QBD) for pharmaceuticals. Int. J. Drug Dev. Res, 7(1), 52-60.
[6] Chauhan, P., Modi, D., Seema Banu, M., Giri, S., Rathod, A., Patel, K. K., & Patel, D. C. (2022). Review on analytical quality by design and pat. World Journal of Pharmaceutical Research, 11(14), 244-266.
[7] Patil, A. S., & Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Pharm Qual Assur, 4(2), 13-9.
[8] Nadpara, N. P., Thamar, R. V., Kalola, V. N., & Patel, P. B. (2012). Quality by design (QBD): A complete review. Int J Pharm Sci Rev Res, 17(2), 20-8.
[9] Abhinandana, P., & Nadendla, R. Application of Quality by Design and its Parameters for Pharmaceutical Products.
[10] Gawade, A., Chemate, S., & Kuchekar, A. (2013). Pharmaceutical Quality by Design: A new approach in product development. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences, 2(3), 5-12.
[11] Khan, A., Naquvi, K. J., Haider, M. F., & Khan, M. A. (2024). Quality by design-newer technique for pharmaceutical product development. Intelligent Pharmacy, 2(1), 122-129.
[12] Patil, H. D., Patil, C. B., Patil, V. V., & Patil, P. S. (2023). An overview on quality by design.
[13] Patel, H., Parmar, S., & Patel, B. (2013). A comprehensive review on quality by design (QbD) in pharmaceuticals. development, 4(5).
[14] Rajora, A., & Chhabra, G. U. R. M. E. E. T. (2021). Quality by design approach: Regulatory need, current, and future perspective. Asian J. Pharm. Clin. Res, 14, 29-35.
[15] Raghav, G., VIPIN, S., SURESH, J., & Ankit, G. (2014). A review on Quality by Design approach: regulatory need. Mintage Journal of Pharmaceutical & Medical Science. Review article, 3(Suppl 3), 20-26.
[16] Mogal, V., Dusane, J., Borase, P., Thakare, P., & Kshirsagar, S. (2016). A review on quality by design. Pharm Biol Eval, 3, 313-9.
[17] Ganzer, W. P., Materna, J. A., Mitchell, M. B., & Wall, L. K. (2005). Current thoughts on critical process parameters and API synthesis. Pharmaceutical technology (2003), 29(7), 46-66.
[18] Mogal, V., Dusane, J., Borase, P., Thakare, P., & Kshirsagar, S. (2016). A review on quality by design. Pharm Biol Eval, 3, 313-9.
[19] Shree, V. M., & Chandramouli, R. (2021). Review on Quality by Design Approach (Qbd). Current Trends in Biotechnology and Pharmacy, 15(4), 447-454.
[20] Sangs Hetti, J. N., Deshpande, M., Zaheer, Z., Shinde, D. B., & Arote, R. (2017). Quality by design approach: Regulatory need. Arabian Journal of chemistry, 10, S3412-S3425.



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY